Autoimmune biomarker profiling in tauopathy

tau 蛋白病中的自身免疫生物标志物分析

基本信息

  • 批准号:
    8433838
  • 负责人:
  • 金额:
    $ 19.17万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-12-01 至 2014-11-14
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Tauopathies are a family of neurodegenerative disorders characterized by the intracellular aggregation of filaments predominantly composed of hyperphosphorylated microtubule-associated protein tau. This family of neurodegenerative disorders includes Alzheimer's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia with Parkinsonism linked to chromosome 17 and Pick disease, among others. Genetics, biochemical and neuropathological studies suggest that disruption of the biological function of tau proteins, either by mutations, hyperphosphorylation and/or aberrant protein interactions, may play a central role in the process of neurodegeneration. However, the molecular mechanisms underlying tau- mediated neurodegeneration are still poorly understood. Recently, the PI's research group has demonstrated that Amphiphysin-1 (AMPH1) protein level is significantly reduced in the tauopathy mouse model JNPL3 and AD cases. The reduction in AMPH1 protein level is associated with detection of pathological tau in terminally ill JNPL3 mice and AD. AMPH1 is a scaffold protein essential for clatherin-coated vesicle endocytosis, which plays an important role in synaptic activity and its deletion leads to cognitive impairment. Importantly, the presence of anti-AMPH1 antibodies in human serum has been correlated with a neurological disorder known as Stiff-person-syndrome. The autoimmune response that leads to the generation of anti-AMPH1 antibodies is unknown. Preliminary studies showed that terminally ill JNPL3 mice generated detectable self-AMPH1 antibodies in the serum. The detection of the self-AMPH1 antibodies correlates with reduction in the level of AMPH1 protein, suggesting that neurodegeneration in this tauopathy mouse model may lead to the disruption of self-tolerance mechanisms. Therefore, in order to characterize and validate the production of autoimmune antibodies in tau-mediated neurodegeneration the following two specific objectives will be addressed: (1) To characterize and validate the autoimmune response that lead to self-AMPH1 antibodies in tauopathies; (2) To identify autoimmune biomarkers in tau-mediated neurodegeneration. The results obtained will contribute to the identification of disease-specific protein biomarkers that could serve as diagnostic tools and for the better understanding of the pathobiology of tau-mediated neurodegeneration. Importantly, the research plan provides an opportunity to train undergraduate and graduates students on the importance of translating basic biomedical research into applied research in the quest to provide insights on diseases that afflict the general population, such as AD.
描述(由申请人提供):Tau病是一个神经退行性疾病家族,其特征在于主要由过度磷酸化微管相关蛋白tau组成的细丝的细胞内聚集。该神经退行性疾病家族包括阿尔茨海默病、皮质基底节变性、进行性核上性麻痹、与17号染色体相关的额颞叶痴呆伴帕金森综合征和皮克病等。遗传学、生物化学和神经病理学研究表明,通过突变、过度磷酸化和/或异常蛋白质相互作用破坏tau蛋白的生物学功能,可能在神经变性过程中发挥核心作用。然而,tau蛋白介导的神经退行性变的分子机制仍然知之甚少。最近,PI的研究小组已经证明,在tau蛋白病小鼠模型JNPL 3和AD病例中,Amphiphysin-1(AMPH 1)蛋白水平显著降低。AMPH 1蛋白水平的降低与终末期疾病JNPL 3小鼠和AD中病理性tau的检测相关。AMPH 1是网格蛋白包被的囊泡内吞所必需的支架蛋白,在突触活动中起重要作用,其缺失导致认知障碍。重要的是,人血清中抗AMPH 1抗体的存在与称为僵人综合征的神经系统疾病相关。导致抗AMPH 1抗体产生的自身免疫反应尚不清楚。初步研究表明,终末期病JNPL 3小鼠在血清中产生可检测的自身AMPH 1抗体。自身AMPH 1抗体的检测与AMPH 1蛋白水平的降低相关,表明这种tau蛋白病小鼠模型中的神经变性可能导致自身耐受机制的破坏。因此,为了表征和验证tau介导的神经变性中自身免疫抗体的产生,将解决以下两个具体目标:(1)表征和验证导致tau病变中自身AMPH 1抗体的自身免疫应答;(2)鉴定tau介导的神经变性中的自身免疫生物标志物。所获得的结果将有助于识别疾病特异性蛋白质生物标志物,这些蛋白质生物标志物可作为诊断工具,并有助于更好地理解tau介导的神经变性的病理生物学。重要的是,该研究计划提供了一个机会,培训本科生和研究生将基础生物医学研究转化为应用研究的重要性,以提供对困扰普通人群的疾病(如AD)的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

IRVING E VEGA其他文献

IRVING E VEGA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('IRVING E VEGA', 18)}}的其他基金

Commumity Liaison and Recruitment Core
社区联络和招聘核心
  • 批准号:
    10729667
  • 财政年份:
    2018
  • 资助金额:
    $ 19.17万
  • 项目类别:
Bridge to the PhD in Neuroscience
通往神经科学博士学位的桥梁
  • 批准号:
    10403941
  • 财政年份:
    2015
  • 资助金额:
    $ 19.17万
  • 项目类别:
Bridge to the PhD in Neuroscience
通往神经科学博士学位的桥梁
  • 批准号:
    10612522
  • 财政年份:
    2015
  • 资助金额:
    $ 19.17万
  • 项目类别:
Autoimmune biomarker profiling in tauopathy
tau 蛋白病中的自身免疫生物标志物分析
  • 批准号:
    8970227
  • 财政年份:
    2012
  • 资助金额:
    $ 19.17万
  • 项目类别:
The role of a novel tau-associated protein in neurodegeneration
一种新型 tau 相关蛋白在神经退行性变中的作用
  • 批准号:
    7627031
  • 财政年份:
    2009
  • 资助金额:
    $ 19.17万
  • 项目类别:
The role of a novel tau-associated protein in neurodegeneration
一种新型 tau 相关蛋白在神经退行性变中的作用
  • 批准号:
    7900365
  • 财政年份:
    2009
  • 资助金额:
    $ 19.17万
  • 项目类别:
The role of a novel tau-associated protein in neurodegeneration
一种新型 tau 相关蛋白在神经退行性变中的作用
  • 批准号:
    8292117
  • 财政年份:
    2009
  • 资助金额:
    $ 19.17万
  • 项目类别:
The role of a novel tau-associated protein in neurodegeneration
一种新型 tau 相关蛋白在神经退行性变中的作用
  • 批准号:
    8117084
  • 财政年份:
    2009
  • 资助金额:
    $ 19.17万
  • 项目类别:
Proteome analysis in mice expressing P301L tau
表达 P301L tau 的小鼠的蛋白质组分析
  • 批准号:
    6844690
  • 财政年份:
    2004
  • 资助金额:
    $ 19.17万
  • 项目类别:
Proteome analysis in mice expressing P301L tau
表达 P301L tau 的小鼠的蛋白质组分析
  • 批准号:
    6738256
  • 财政年份:
    2004
  • 资助金额:
    $ 19.17万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了